RxDoctor Payments Data

Harlan Weiss, MD

Internal Medicine · Bossier City, LANPI 1932215456

Payments from drug & device makers

$1,171in general payments, 2019–2025

Across 29 payments — averaging $40.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$197
  • AstraZeneca$154
  • E.r. Squibb & Sons, L.L.C.$126
  • Astellas Pharma US Inc$125
  • AbbVie$125
  • Otsuka America Pharmaceutical, Inc.$125
  • plus $319 from 8 others

What the payments were for

  • Food & beverage$1,171100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,171 in reported general payments places this provider in the 65th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$25,983
Medicare patients
81
Services billed
442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$74,650
Invega SustennaPaliperidone Palmitate20$62,596
MounjaroTirzepatide38$52,584
JardianceEmpagliflozin31$38,728
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$38,268
LinzessLinaclotide27$34,815
EliquisApixaban29$29,786
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl80$16,434
TradjentaLinagliptin16$15,809
FarxigaDapagliflozin Propanediol17$15,319
MyrbetriqMirabegron16$10,082
SymbicortBudesonide/Formoterol Fumarate16$6,556
Buprenorphine Hcl87$4,718
Albuterol Sulfate HfaAlbuterol Sulfate125$4,053
Atorvastatin Calcium360$2,839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$115$38,26831 claims
AbbVieLinzess$125$34,81527 claims
PfizerEliquis$39$29,78629 claims
AstraZenecaFarxiga, Symbicort$154$21,87533 claims
Astellas Pharma US IncMyrbetriq$125$10,08216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Bossier City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →